Bicycle Therapeutics is a biotechnology business based in the US. Bicycle Therapeutics shares (BCYC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $20.36 – a decrease of 6.56% over the previous week. Bicycle Therapeutics employs 284 staff and has a trailing 12-month revenue of around $36.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $20.36 |
|---|---|
| 52-week range | $13.07 - $28.67 |
| 50-day moving average | $24.55 |
| 200-day moving average | $23.11 |
| Wall St. target price | $37.82 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.28 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $20.36 from 2024-11-20
| 1 week (2024-11-14) | -9.83% |
|---|---|
| 1 month (2024-10-21) | -23.75% |
| 3 months (2024-08-21) | -9.63% |
| 6 months (2024-05-21) | -5.74% |
| 1 year (2023-11-21) | 51.26% |
|---|---|
| 2 years (2022-11-21) | -23.80% |
| 3 years (2021-11-19) | 58.13 |
| 5 years (2019-11-21) | 136.19% |
| Revenue TTM | $36.9 million |
|---|---|
| Gross profit TTM | $-67,146,000 |
| Return on assets TTM | -15.02% |
| Return on equity TTM | -26.67% |
| Profit margin | 0% |
| Book value | $12.04 |
| Market Capitalization | $1.6 billion |
TTM: trailing 12 months
We're not expecting Bicycle Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Bicycle Therapeutics's shares have ranged in value from as little as $13.07 up to $28.6701. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bicycle Therapeutics's is 0.892. This would suggest that Bicycle Therapeutics's shares are less volatile than average (for this exchange).
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.